Duncan Peyton, 4D’s Chief Executive Officer, commented: “This is an important year for 4D as we start to see clinical readouts from our lead programmes. Our focus on understanding bacterial function and mechanism to select the most potent single strain Live Biotherapeutics as well as our continued progress to evaluate them in the clinic is reflected in our presentation. 4D’s approach has numerous advantages including accelerated speed into clinical trials and a clear regulatory pathway to market.”
4D pharma plc (LON: DDDD), a pharmaceutical company leading the development of Live Biotherapeutics, today announces its participation in the inaugural Chardan Capital Markets LLC Microbiome Medicines Summit.
Alex Stevenson, 4D’s Chief Scientific Officer, gave a presentation on 4D’s core focus programmes in oncology, gastrointestinal disease, respiratory and CNS disease.
